Number 3: Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab ...
Alvotech (NASDAQ: ALVO, or the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ: ALVO), a global biotech ...
Biogen Inc's version of AbbVie Inc's blockbuster arthritis drug Humira has been approved by European Union regulators, Biogen and joint venture partner Samsung Biologics said on Thursday.
Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will ...
AbbVie, known for its strong presence in immunology and oncology, has demonstrated resilience in the face of Humira’s patent expiration. The company reported robust financial results in the fourth ...
On Wednesday, 12 March 2025, Alvotech (NASDAQ: ALVO) presented at the Barclays 27th Annual Global Healthcare Conference 2025. The company emphasized its strategic focus on biosimilars, noting ...
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosimilar market with their robust R&D capabilities and ...
Humira sales peaked in 2022 at more than $21 billion, or more than 37% of AbbVie's total sales. However, consumers can now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback